391 related articles for article (PubMed ID: 25774503)
1. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
2. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
[TBL] [Abstract][Full Text] [Related]
3. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.
Ben-Shlomo A; Deng N; Ding E; Yamamoto M; Mamelak A; Chesnokova V; Labadzhyan A; Melmed S
J Clin Invest; 2020 Nov; 130(11):5738-5755. PubMed ID: 32673291
[TBL] [Abstract][Full Text] [Related]
4. Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line.
Fukuda T; Tanaka T; Hamaguchi Y; Kawanami T; Nomiyama T; Yanase T
PLoS One; 2016; 11(10):e0164131. PubMed ID: 27706259
[TBL] [Abstract][Full Text] [Related]
5. Rab18 is reduced in pituitary tumors causing acromegaly and its overexpression reverts growth hormone hypersecretion.
Vazquez-Martinez R; Martinez-Fuentes AJ; Pulido MR; Jimenez-Reina L; Quintero A; Leal-Cerro A; Soto A; Webb SM; Sucunza N; Bartumeus F; Benito-Lopez P; Galvez-Moreno MA; Castaño JP; Malagon MM
J Clin Endocrinol Metab; 2008 Jun; 93(6):2269-76. PubMed ID: 18349058
[TBL] [Abstract][Full Text] [Related]
6. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
7. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
9. Lentiviral vectors efficiently transduce human gonadotroph and somatotroph adenomas in vitro. Targeted expression of transgene by pituitary hormone promoters.
Roche C; Zamora AJ; Taïeb D; Lavaque E; Rasolonjanahary R; Dufour H; Bagnis C; Enjalbert A; Barlier A
J Endocrinol; 2004 Oct; 183(1):217-33. PubMed ID: 15525589
[TBL] [Abstract][Full Text] [Related]
10. Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma.
Ashton C; Rhie SK; Carmichael JD; Zada G
J Neurosurg; 2020 Feb; 134(3):787-793. PubMed ID: 32109873
[TBL] [Abstract][Full Text] [Related]
11. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells.
Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C
J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434
[TBL] [Abstract][Full Text] [Related]
12. The aging suppressor klotho: a potential regulator of growth hormone secretion.
Shahmoon S; Rubinfeld H; Wolf I; Cohen ZR; Hadani M; Shimon I; Rubinek T
Am J Physiol Endocrinol Metab; 2014 Aug; 307(3):E326-34. PubMed ID: 24939736
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.
Acunzo J; Thirion S; Roche C; Saveanu A; Gunz G; Germanetti AL; Couderc B; Cohen R; Figarella-Branger D; Dufour H; Brue T; Enjalbert A; Barlier A
Cancer Res; 2008 Dec; 68(24):10163-70. PubMed ID: 19074883
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-secreting adenomas: pathology and cell biology.
Lopes MB
Neurosurg Focus; 2010 Oct; 29(4):E2. PubMed ID: 20887127
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide stimulates growth hormone secretion from human fetal pituitaries and cultured pituitary adenomas.
Rubinek T; Rubinfeld H; Hadani M; Barkai G; Shimon I
Endocrine; 2005 Nov; 28(2):209-16. PubMed ID: 16388095
[TBL] [Abstract][Full Text] [Related]
17. In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.
Cuny T; Zeiller C; Bidlingmaier M; Défilles C; Roche C; Blanchard MP; Theodoropoulou M; Graillon T; Pertuit M; Figarella-Branger D; Enjalbert A; Brue T; Barlier A
Endocr Relat Cancer; 2016 Jul; 23(7):509-19. PubMed ID: 27267119
[TBL] [Abstract][Full Text] [Related]
18. A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone--an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture.
Matsuno A; Sasaki T; Mochizuki T; Fujimaki T; Sanno N; Osamura Y; Teramoto A; Kirino T
Acta Neurochir (Wien); 1996; 138(8):1002-7. PubMed ID: 8890999
[TBL] [Abstract][Full Text] [Related]
19. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
Ishibashi M; Yamaji T
J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
